Introduction
Among the main therapeutic targets to be reached in type 2 diabetic patients are the gluco-metabolic pattern improvement and the body weight reduction (1) . Intensive programs aimed at reducing calories (2) intake and at increasing physical activity (3) have clearly shown to improve the metabolic control of obese diabetic patients. However, the behavioural approach is usually slow and not always sufficient to get the optimal targets of weight and metabolic control in obese diabetic patients and a pharmacological treat-ment has often to be planned in order to significantly and quickly reduce their high cardiovascular disease risk (4) . On the other side, a pharmacological treatment for overweight or obese state is sometime necessary, because of the neutralto-armful effect of the most part of antidiabetic treatments on body weight (5) . In fact, the insulin-sensitivity improvement associated to the use of some antidiabetic drugs could lead to a further accumulation of adipose tissue (6) , even if mainly located in the subcutaneous tissue and not in the more dangerous visceral one. The only antidiabetic treatment with neutral to positive effect on body weight is metformin, but at full dosage it is not well tolerated by all patients (5) . A therapeutic alternative in metformin-intolerant patients could be thiazolidinediones, that are supposed to be the pharmacological agents that more physiologically fight the insulin-resistance associated to obesity, decreasing resistin and increasing adiponectin, both in animal models and in humans (7) , however their use is also often associated to body weight increase (7) . This (14) .
Materials and Methods

Study design
F i g u r e 1 . T o t a l p a t i e n t s e n r o l l e d i n t h e s t u d y , p a t i e n t s n u mb e r wi t h s i d e e f f e c t s a n d t y p e o f s i d e e f f e c t s .
F i g u r e 2 . S t u d y d e s i g n .
Total cholesterol and triglycerides levels were determined using fully enzymatic techniques (15, 16) T a b l e 1 . P a r a me t e r Ch a n g e s a t 3 , a n d 6 Mo n t h s i n b o t h Gr o u p s d u r i n g t h e S t u d SBP: systolic blood pressure; DBP: diastolic blood pressure; HR: heart rate.
Results
Anthropometric parameters
No body mass index and waist circumference change was observed at 3, and 6 months in pioglitazone + sibutramine group. A significant reduction of body mass index and waist circumference was observed after 6 months in metformin + sibutramine group (p<0.05, respectively). There was no significant difference between the two groups (Table 1).
Glycemic control
Lipid profile
No significant total cholesterol, LDL-C, and HDL-C change was observed at 3, and 6 months, while a significant triglycerides reduction was present after 6 months (p<0.05) in both groups respect to the baseline values. There was not difference in triglycerides value between the two groups (Table 1).
Blood pressure
No systolic blood pressure and diastolic blood pressure change was obtained after 3, and 6 months in both groups (Table 1) . No significant heart rate variation was obtained during the study in both groups (Table 1) .
Discussion
Both type 2 diabetes and obesity are associated with severe insulin resistance and compensatory hyperinsulinemia (20) . In type 2 diabetes, insulin-resistance is a substantially inherited metabolic defect, whereas obesity and its consequent insulin-resistance may be due to either excessive caloric intake or an inherited disturbance in thermogenesis or intermediary metabolism (21) . In both cases, the main pathophysiological approach to the therapy is the reduction of insulin-resistance through intensive life-style modification and specific pharmacotherapy (22) . The more widely known, tested and used insulin-sensitizing agent is the biguanide metformin: its use is generally safe, but when administered at full-dosage its tolerability decreases thus reducing the patient compliance to the therapy (23) .
In (24) , a preventive effect on cardiovascular disease (25) and a nearly neutral effect on body weight (26) .
Several concerns have been recently raised on the cardiovascular safety of thiazolidinediones use in diabetic patients (27) . However, it seems that they regard more strictly rosiglitazone than pioglitazone (28) . Moreover, in this study as in our several ones carried out with pioglitazone (29) (30) (31) the simple application of exclusion criteria suggested by the international literature and guidelines (32) 
